Advertisement

Search Results

Advertisement



Your search for ,HIS matches 4456 pages

Showing 701 - 750


gastroesophageal cancer

New Research Aims to Uncover Cellular Source of Barrett’s Esophagus

Two recent studies correct a long-standing misconception about the origins of Barrett’s esophagus and, in doing so, may point to new avenues of treatment or prevention to lower the risk of esophageal cancer. The first study, published by Singh et al in the journal Gastroenterology, demonstrated...

colorectal cancer

Does Geography Play a Role in Early-Onset Colorectal Cancer in Young Black Men?

Although the incidence and mortality rates in colorectal cancer have dropped by 3.6% each year from 2007 to 2016 for people aged 55 and older—mainly because of increased colorectal cancer screening, advances in therapy, and reductions in smoking—these rates have increased by 2% each year during the ...

lung cancer

Smoking Cessation After Lung Cancer Diagnosis May Improve Overall Survival

Patients with lung cancer who quit smoking after their diagnosis experienced improvement in their overall survival compared to patients who continued smoking after diagnosis, according to results from a meta-analysis published by Caini et al in the Journal of Thoracic Oncology. Researchers led by...

lymphoma
genomics/genetics

Joe Schroers-Martin, MD, on Follicular Lymphoma: Precursor Mutations May Be Detectable Years Before Diagnosis

Joe Schroers-Martin, MD, of Stanford University, discusses his latest study findings, which show that follicular lymphoma driver mutations are detectable in blood and saliva years prior to a clinical diagnosis. These data build on previous work and suggest that researchers may be able to stratify...

global cancer care

Study Examines Global Cancer Burden From 2010 to 2019

Cancer deaths rose to 10 million and new cases jumped to over 23 million globally in 2019, according to a new study from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington School of Medicine published in JAMA Oncology. At the start of the decade in 2010, total...

multiple myeloma
immunotherapy
genomics/genetics

Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma

Molecular and genetic research has advanced the categorization of different risk groups in patients with smoldering myeloma. Notable presentations at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition included reports on biomarkers to predict response to immunotherapy in...

ASH Recognizes Peter Marks, MD, PhD, With 2021 Outstanding Service Award

The American Society of Hematology (ASH) recognized Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), for his outstanding commitment to hematology in overseeing the approval of therapeutics that improve the...

breast cancer

Expert Point of View: Matthew J. Ellis, MB, BChir, PhD, FACP

The final results of the phase III PALLAS trial1 are “deeply disappointing,” said session moderator Matthew J. Ellis, MB, BChir, PhD, FACP, Professor of Medicine and Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine. The results of the final primary analysis of PALLAS ...

breast cancer

Final Analysis of PALLAS Trial: No Benefit of Adjuvant Palbociclib Plus Endocrine Therapy in Early Breast Cancer

The final protocol-defined analysis of the phase III PALLAS trial confirmed the negative results of the second interim analysis, showing no benefit of palbociclib plus endocrine therapy in the adjuvant breast cancer setting. Michael Gnant, MD, of the Medical University of Vienna, reported these...

colorectal cancer

I Don’t Know Why I Got Young-Onset Colorectal Cancer

Throughout my adolescence and early adulthood, I had been plagued with digestive issues, including bouts of gastritis and constipation, which seemed normal for me and wasn’t too concerning. But by the time I turned 30, in 2015, the acid reflux I had been experiencing became so frequent and...

UC Davis Brain Surgeon Appointed to Co-lead Cancer Center Biomedical Technology Program

Professor and neurosurgical oncologist Orin Bloch, MD, FAANS, has been appointed as the new co-leader of UC Davis Comprehensive Cancer Center’s Biomedical Technology Program effective December 1. Dr. Bloch is replacing Chief of Nuclear Medicine Ramsey Badawi, PhD, who is stepping down from the role ...

covid-19

Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective

The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...

lymphoma
immunotherapy

Roni Shouval, MD, PhD, on TP53-Mutant Large B-Cell Lymphoma and CAR T-Cell Therapy

Roni Shouval, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses his findings, which show, for the first time, that TP53 alterations are a valuable prognostic and potentially predictive marker in patients with large B-cell lymphoma who receive CD19–CAR T-cell therapy. Gene-expression...

leukemia

Masayuki Umeda, MD, on Pediatric AML: Identifying a Key Subtype-Defining Lesion

Masayuki Umeda, MD, of St. Jude Children's Research Hospital, discusses his research which showed that UBTF-TD (upstream binding transcription factor-tandem duplications) define a unique subtype of acute myeloid leukemia that previously lacked a clear oncogenic driver. UBTF-TD is associated with...

HHS Secretary Becerra Names Lawrence Tabak, DDS, PhD, Acting Director of NIH

Health and Human Services Secretary Xavier Becerra recently announced that Lawrence A. Tabak, DDS, PhD, Principal Deputy Director of the National Institutes of Health (NIH), will serve as Acting Director of the NIH effective December 20, 2021.   Earlier this year, current NIH Director Francis S....

lung cancer

I’m Living—and Thriving—With Stage IV Non–Small Cell Lung Cancer

A diagnosis, in 2020, of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) was found accidentally. I was 55 at the time and in the best physical shape of my life. I had spent the previous year and a half on a diet and exercise regimen that had rendered me 35 pounds lighter and feeling...

Nagi El Saghir, MD, FACP, Receives the Susan Bulkeley Butler Leadership Excellence Award

On October 29, 2021, Nagi El Saghir, MD, FACP, received the 2019 Susan Bulkeley Butler Leadership Excellence Award: Making Strides in Cancer Prevention. Because of pandemic-related delays, the award was presented at the 10th International Breast Cancer and Nutrition (IBCN) meeting, hosted by...

pain management

The High Price of Pain

According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2019, nearly 247,000 people died from overdoses involving prescription opioids in the United States. According to the CDC, the problem can be broken into three waves. The first began with an increase in prescribing...

Reclaiming a Complicated Genius Who Pursued Cancer With Single-Minded Fury

The Nobel Laureate Otto Warburg was regarded as one of the most significant biochemists of the 20th century, whose exhaustive research led to an understanding of cancer that remains significant to this day. Warburg was also one of the most despised figures in his homeland of Nazi Germany. As a...

Erudition and Assessment on the Longest War in the Modern Era

A little after noon on December 23, 1971, President Richard Nixon entered the White House state dining room. Before 137 esteemed guests from government, science, and industry, he signed the landmark National Cancer Act. It was, in short, a national commitment to conquer cancer. President Nixon...

Early Operation With General Anesthesia

The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...

The History of Medical Oncology in Europe, 1955–1985

In part 1 of this two-part review, we looked at early pioneers in the field of medical oncology in Europe, as well as the development of international cooperative trials and the formation of European oncology societies (see related articles below). In part 2, we explore how the field of medical...

ACCC Presents 2021 Annual Awards for Significant Contributions to Oncology Care

The Association of Community Cancer Centers (ACCC) presented its 2021 Annual Awards at the its 38th National Oncology Conference, held virtually on November 9–10. The awards honor individuals who have made significant contributions to patient care, the practice of clinical care and research, and...

Three Investigators Named Winners of MSK Cancer Center’s 2021 Paul Marks Prize for Cancer Research

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three recipients of this year’s Paul Marks Prize for Cancer Research. The prize recognizes a new generation of leaders in cancer research who are making significant contributions to the understanding of cancer or are improving the...

Mammen Chandy, MD, FRACP, FRACPA: A Pioneer in India’s Bone Marrow Transplantation Services

In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with bone marrow transplant expert Mammen Chandy, MD, FRACP, FRACPA, Director of Tata Medical Center, in Kolkata, India. Dr. Chandy was instrumental in establishing the first sustained bone marrow...

Cancer Researcher and Biotech Founder Lewis Cantley, PhD, Joins Dana-Farber

Lewis Cantley, PhD, the cancer researcher best known for his discovery of the PI3K pathway and his groundbreaking work on cancer metabolism, will be joining the Dana-Farber Cancer Institute in February 2022. Dr. Cantley’s move from his current position as Director of the Sandra and Edward Meyer...

Mitchell D. Schnall, MD, PhD, Re-elected Group Co-Chair of the ECOG-ACRIN Cancer Research Group

The Principal investigator Committee of the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) re-elected Mitchell D. Schnall, MD, PhD, as the Group Co-Chair, a position he has held since the founding of the Group in 2012. Dr. Schnall will serve in this role from 2021 to 2031. Dr. Schnall co-leads the...

The History of Medical Oncology in Europe, 1955–1985

Our goal with this review of the pivotal years of oncology in Europe is to acknowledge the tremendous contributions of the early leaders in the field and to help young investigators learn from the past to better cope with the inevitable challenges of today and tomorrow. “On ne connaît pas...

Jordan’s Queen Rania Presents King Hussein Awards for Cancer Research

Her Majesty Queen Rania Al Abdullah of Jordan honored recipients of the 2021 King Hussein Award for Cancer Research during ceremony held on November 14 by the King Hussein Cancer Foundation (KHCF). The event was conducted under the patronage of Their Majesties King Abdullah II and Queen Rania Al...

integrative oncology

Society for Integrative Oncology Focuses on the Science of Living Well With Cancer

Guest Editor’s Note: With the easing of some COVID-19 restrictions, the Society for Integrative Oncology (SIO) held its 2021 international conference in a hybrid format. It focused on the science of living well with cancer, challenges in designing integrative oncology research, and the role of...

How Medical Oncology Came to Be

For many, the way things are when you learn about them is assumed to be the way things have always been. For example, antibiotics are wonderful—but if you were practicing medicine when penicillin was discovered, it would have seemed like a miracle. For most of us, there have always been chemical...

issues in oncology

Establishing a Health Equity Report Card to Eradicate Disparities in Cancer Care

Although enormous progress over the past 50 years in every aspect of cancer care, including prevention, screening, chemotherapy, targeted therapy, surgery, radiation therapy, and supportive care, has resulted in increases in lives saved—from 3 million in 1971 to 16.9 million in 2019—the burden of...

multiple myeloma
covid-19

COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response

Patients with multiple myeloma lacking an antibody response to COVID-19 vaccination may also fail to mount a T-cell response, researchers from the Icahn School of Medicine at Mount Sinai have reported. This scenario seemed to be most common among patients actively treated with anti-CD38 and...

immunotherapy
covid-19

Jeffrey Weber, MD, PhD, on Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment

Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, offers his perspective on the impact of the COVID-19 pandemic on oncology care and cancer clinical trials, as clinicians strive to provide optimal treatment to patients while reducing their risk of contracting the coronavirus. The steep decline ...

SARC Appoints Jonathan Fletcher, MD, to New Role of Chief Scientific Officer

Sarcoma Alliance for Research Through Collaboration (SARC) recently announced the appointment of Jonathan ­Fletcher, MD, as Chief Scientific Officer (CSO). This is a new role at the nonprofit cancer research organization, a leader in collaborative discovery, translational research, and clinical...

Eric P. Winer, MD, FASCO, to Lead Yale Cancer Center and Smilow Cancer Hospital

After an extensive national search, Yale School of Medicine and Yale New Haven Health have announced that Eric P. Winer, MD, FASCO, will be the next Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven, effective February 1, 2022. Nita Ahuja, MD, MBA,...

Passionate About Surgical Oncology, Masakazu Toi, MD, PhD, Is a Leader in Japanese Clinical Trials

In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Masakazu Toi, MD, PhD, a clinical breast cancer expert who is keen on research that translates basic science into clinical study. He is involved in various innovative research projects on the development ...

palliative care

The Role of Spirituality in Palliative Care

National surveys consistently show that spirituality and religion are important components in the lives of most Americans, with more than 90% of adults expressing a belief in God and more than 70% identifying religion as one of the most important influences in their lives.1 Studies also show that...

Northwell Names Fidel Valea, MD, to Leadership Roles in Gynecologic Oncology

Fidel Valea, MD, recently announced his appointment as System Chief of Gynecologic Oncology at Northwell Health and Director of Gynecologic Oncology at the Northwell Health Cancer Institute. He will see patients in New Hyde Park, New York, and Manhattan. In his role as System Chief of Gynecologic...

Craig Sauter, MD, Joins Cleveland Clinic

Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at the Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, recently announced the appointment of Craig Sauter, MD, as the new Director of Blood and Marrow Transplant Program at the Cleveland...

MSK Appoints Saad Z. Usmani, MD, MBA, FACP, Chief of Myeloma Service

Physician leader and clinical and translational investigator Saad Z. Usmani, MD, MBA, FACP, recently joined Memorial Sloan Kettering Cancer Center (MSK) as Chief of Myeloma Service. He was also appointed Professor at the Joan & Sanford I. Weill Medical College of Cornell University. Dr....

Purdue Center for Cancer Research Receives $1.5 Million for Endowed Professorship

The Henry E. Haller Jr. Foundation and the Walther Cancer Foundation together will donate a total of $1.5 million to the Purdue Center for Cancer Research and the College of Science in Cancer Biology in West Layfayette, Indiana. A donation of $750,000 from the Henry E. Haller Jr. Foundation was...

issues in oncology
global cancer care

Choosing Wisely, Researchers Look at Access to Essential Cancer Drugs on a Global Scale

According to the International Agency for Research on Cancer (IARC), an estimated 19.3 million new cancer cases occurred worldwide in 2020, resulting in almost 10 million deaths. The IARC projects a 50% rise in global cancer incidence and mortality by 2040. To help control this looming crisis,...

Expert Point of View: Steven J. Chmura, MD, PhD

At a press conference at the 2021 ASTRO Annual Meeting, Steven J. Chmura, MD, PhD, Professor of Radiation Oncology and Scientific Director of the Cancer Clinical Trials Office, University of Chicago, commented on the CURB study results. “Most trials of stereotactic body radiation therapy (SBRT)...

President Biden Nominates Robert M. Califf, MD, MACC, as FDA Commissioner

President Joseph Biden has nominated Robert M. Califf, MD, MACC, for the position of Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Califf is an internationally recognized expert in clinical trial research, health disparities, health-care quality, and cardiovascular medicine....

Expert Point of View: Farzan Siddiqui, MD, PhD

“MC1675 is an important and exciting trial,” stated invited discussant Farzan Siddiqui, MD, PhD, of the Henry Ford Cancer Institute, Detroit. “Congratulations to the authors and to Dr. Ma for his award.” “There is strong evidence to suggest that patients with HPV-positive oropharyngeal cancers...

head and neck cancer

De-escalation of Radiation Therapy for HPV-Positive, Intermediate-Risk Oropharyngeal Cancer

De-escalated adjuvant radiotherapy appears to be safe in patients with surgically resectable, human papillomavirus (HPV)--positive oropharyngeal cancers, particularly in patients without extranodal extension or pN2 disease by American Joint Committee on Cancer (AJCC) 8th edition. These findings...

prostate cancer

No Survival Benefit but Improved Secondary Endpoints With Radiotherapy Plus Androgen Suppression in Intermediate-Risk Prostate Cancer

Both dose-escalated radiation therapy and short-course androgen-deprivation therapy have been shown to improve outcomes in intermediate-risk prostate cancer, but it is not clear whether giving both modalities upfront to newly diagnosed patients is of benefit. The phase III RTOG 0815 study presented ...

Second Surprise Billing Rule Covers Dispute Resolution Processes, Good Faith Estimates for the Uninsured

On September 30, 2021, the U.S. Department of Health and Human Services (HHS), the Department of Labor, and the Department of the Treasury (“the Departments”), along with the Office of Personnel Management, released an interim final rule with comment period, entitled “Requirements Related to...

David Morse Livingston, MD, Scientist and Esteemed Mentor, Dies at 80

David Morse Livingston, MD, formerly the Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber and the Emil Frei III Distinguished Professor of Medicine at Harvard Medical School, died unexpectedly on October 17, 2021. He was Deputy Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) ...

Advertisement

Advertisement




Advertisement